359 related articles for article (PubMed ID: 32742136)
1. Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review.
Watson C; Tallentire CW; Ramage JK; Srirajaskanthan R; Leeuwenkamp OR; Fountain D
World J Gastroenterol; 2020 Jul; 26(25):3686-3711. PubMed ID: 32742136
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
[TBL] [Abstract][Full Text] [Related]
3. Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours.
Martini C; Gamper EM; Wintner L; Nilica B; Sperner-Unterweger B; Holzner B; Virgolini I
Health Qual Life Outcomes; 2016 Sep; 14(1):127. PubMed ID: 27614762
[TBL] [Abstract][Full Text] [Related]
4. Quality of Life in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy: Information from a Monitoring Program in Clinical Routine.
Martini C; Buxbaum S; Rodrigues M; Nilica B; Scarpa L; Holzner B; Virgolini I; Gamper EM
J Nucl Med; 2018 Oct; 59(10):1566-1573. PubMed ID: 30042164
[TBL] [Abstract][Full Text] [Related]
5. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion.
Yoo C; Oh CR; Kim ST; Bae WK; Choi HJ; Oh DY; Lee MA; Ryoo BY
Cancer Res Treat; 2021 Apr; 53(2):291-300. PubMed ID: 33421978
[TBL] [Abstract][Full Text] [Related]
6. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
7. GEP-NET radiomics: a systematic review and radiomics quality score assessment.
Staal FCR; Aalbersberg EA; van der Velden D; Wilthagen EA; Tesselaar MET; Beets-Tan RGH; Maas M
Eur Radiol; 2022 Oct; 32(10):7278-7294. PubMed ID: 35882634
[TBL] [Abstract][Full Text] [Related]
8. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.
Jin XF; Spampatti MP; Spitzweg C; Auernhammer CJ
Rev Endocr Metab Disord; 2018 Jun; 19(2):145-158. PubMed ID: 29464446
[TBL] [Abstract][Full Text] [Related]
9. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
Perez K; Chan J
Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
[TBL] [Abstract][Full Text] [Related]
11. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
12. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
13. Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors.
Riff BP; Yang YX; Soulen MC; Pryma DA; Bennett B; Wild D; Nicolas G; Teitelbaum UR; Metz DC
Clin Nucl Med; 2015 Nov; 40(11):845-50. PubMed ID: 26284763
[TBL] [Abstract][Full Text] [Related]
14. Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors.
Naraev BG; Mailman J; Halfdanarson TR; Soares HP; Mittra ES; Hallet J
Expert Rev Anticancer Ther; 2023 Jun; 23(6):601-615. PubMed ID: 37158050
[TBL] [Abstract][Full Text] [Related]
15. New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors.
Scoville SD; Cloyd JM; Pawlik TM
Expert Opin Pharmacother; 2020 Feb; 21(2):183-191. PubMed ID: 31760823
[No Abstract] [Full Text] [Related]
16. Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient-Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context.
Wagner M; Samaha D; Cuervo J; Patel H; Martinez M; O'Neil WM; Jimenez-Fonseca P
Adv Ther; 2018 Aug; 35(8):1215-1231. PubMed ID: 29987525
[TBL] [Abstract][Full Text] [Related]
17. Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.
Khan MS; Walter T; Buchanan-Hughes A; Worthington E; Keeber L; Feuilly M; Grande E
World J Gastroenterol; 2020 Aug; 26(30):4537-4556. PubMed ID: 32874063
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
Xu JX; Wu DH; Ying LW; Hu HG
World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
[TBL] [Abstract][Full Text] [Related]
19. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
20. Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor.
Tamagno G; Sheahan K; Skehan SJ; Geoghegan JG; Fennelly D; Collins CD; Maguire D; Traynor O; Brophy DP; Cantwell C; Swan N; McGowan L; O'Toole D; O'Shea D
Endocrine; 2013 Oct; 44(2):504-9. PubMed ID: 23471696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
